A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Behçet Disease Clinical Trial

Official title:

A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04609397
• Other study ID #: HM005BD2S01
• Status: Terminated
• Phase: Phase 2
• Start date: November 30, 2020
• Est. completion date: April 30, 2022

Study information

• Verified date: June 2022
• Source: Ganzhou Hemay Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 12weeks and a follow up phase for 4weeks.

Description:

this study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study to evaluate Hemay005 efficacy and safety of the treatment of patients with Behçet Disease(BD). Around 252 subjects will be randomized into this study. The whole study will including 4 phases that a screening phase, core-treatment phase(12weeks), extended-treatment phase (12weeks) and follow-up phase(4 weeks). Screening: All subjects will undergo a screening period of up to 6 weeks prior to baseline visit (visit 2, day of randomization, Day0). Core treatment phase: eligible BD patients will randomly assigned to Hemay005 high-dose group, Hemay005 low-dose group, placebo (core treatment phase) + Hemay005 high-dose group (extended treatment phase), or placebo (core treatment phase) + Hemay005 low-dose group (extended treatment phase). During the core-treatment period, hemay005 will be administered twice daily for 12 weeks. The randomization was stratified to minimize the imbalance between treatment groups. Extended treatment phase: Subjects in the high-dose and low-dose groups during the extended treatment period will still given the dose of core-treatment phase for 12 weeks. Subjects who received placebo during the core treatment will assigned to either a high-dose group or a low-dose group according the allocation at visit 2 until 12 weeks after. During this period, the subject and investigator are remain blind at this stage. Follow up phase: Subjects in the study (also including those who withdraw from treatment for any reason) will have another follow up for 4 weeks after the end of the last administration.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 89
• Est. completion date: April 30, 2022
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1.Understand and voluntarily sign an informed consent form prior to any study related assessments/procedures being conducted.
• 2.Male and female subjects 18~75(inclusive) years of age at the time of signing the informed consent form.
• 3.Diagnosed with Behçet's disease meeting the International Study Group (ISG) criteria (2013).
• 4.Subjects must have at least 2 oral ulcers at V1, and:

1. at least 2 oral ulcers at V2 if V2 occurs at least 14 days after Visit 1, OR

2. at least 3 oral ulcers at V2 if V2 occurs at least 0~42 days after Visit 1.

• 5. According to the site investigator judgement, subject is suitable to the systemic but not topical treatment of oral ulcer considering the severity and affected area of the disease OR the oral ulcer cannot be well controlled by topical treatment and have to take the systemic treatment.
• 6.All females of childbearing potential (FCBP) and male subjects who did not receive the vasectomy must take effective contraceptive measures.

Exclusion Criteria:

• 1.subject has the BD related major organ activity lesions requiring immunosuppressive therapy- pulmonary, vascular, gastrointestinal, and central nervous systems (eg,

meningoencephalitis) manifestations, etc. However:

1. Previous major organ involvement is allowed if it occurred at least one years prior to screening visit and is not active at time of enrollment.

2. Subjects with BD-related arthritis and BD-skin manifestations are also allowed

• 2. Any clinically significant heart disease (e.g., but not limited to unstable ischemic heart disease, New York Heart Association(NYHA) class III / IV left ventricular failure, or myocardial infarction) or clinically significant 12 lead ECG abnormalities found during screening, which, according to the investigator's judgment, may put the patient at safety risk or may interfere with the investigator;
• 3. subjects who current receiving immunotherapy including:

1. 7 days prior to Visit 2 (randomization) for colchicine.

2. 10 days prior to Visit 2 (randomization) for azathioprine, mycophenolate mofetil, baricitinib or Tofacitinib.

3. 4 weeks prior to visit 2(randomization) for cyclosporin, methotrexate, cyclophosphamide, thalidomide, and dapsone.

4. At least 5 terminal half-lives for all biologics, including,within:

1. Four weeks prior to visit 2(randomization) for etanercept.

2. Eight weeks prior to visit 2(randomization) for infliximab.

3. Ten weeks prior to visit 2(randomization) for adalimumab, golimumab, abatacept, and tocilizumab.

4. Six months prior to visit 2(randomization) for secukinumab.

• 4.Having received intra-articular or parenteral corticosteroids within 6 weeks (42 days) prior to Visit 2.
• 5.Laboratory examination of V1 in screening period:

1. Hemoglobin = 85g / L;

2. The white blood cell (WBC) count was less than 3.0 × 10^9 / L or more than 14 × 10^9 / L;

3. Platelet < 100 × 10^9 / L;

4. Serum creatinine > 1.5mg/dl (> 132.6 µ mol / L);

5. Total bilirubin > 2.0 mg / dl (> 34.2 µ mol / L);

6. The Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) were higher than 1.5 times of the upper limit of normal value.

• 6.subjects who received strong cytochrome P450 enzyme inducer within 4 weeks prior to visit2.
• 7.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C and herpes zoster, histoplasmosis, coccidiomycosis, but excluding onychomycosis) , judged by investigator,may put the patient at safety risk.
• 8.Clinically significant abnormality on chest radiograph or CT,judged by investigator, may put the patient at safety risk.
• 9.History of transplantation and immunodeficiency disease, including those subject has a positive test for human immunodeficiency virus (HIV).
• 10.subject who use of any investigational products of clinical trials within 4 weeks or within 5 pharmacokinetic/pharmacodynamic half-lives prior to randomization, whichever is longer;
• 11.known to be allergic or allergic to the investigational products or ingredients;
• 12.History of alcohol or drug abuse, or a history of mental illness;
• 13.Subjects with severe, progressive, or uncontrolled disease, judged by the investigator, who maybe at risk if participate this study or those subjects whose participation may influence the interpretation of study results.

Related Conditions & MeSH terms

• Behçet Disease
• Behcet Syndrome

Intervention

Drug:
• Hemay005
Hemay005 tables 60mg bid p.o;
• Hemay005
Hemay005 tables 45mg bid p.o

Other:
• Placebo
placebo to Hemay005 tables bid p.o

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of science and technology	Baotou	Inner Mongolia
China	Beijing hospital	Beijing	Beijing
China	Peking Union Medical College Hospital	Beijing	Beijing
China	Peking University First Hospital	Beijing	Beijing
China	Peking University People's Hospital	Beijing	Beijing
China	Peking University Shougang Hospital	Beijing	Beijing
China	Xuanwu Hospital Capital Medical University	Beijing	Beijing
China	The First Affiliated Hospital of Bengbu Medical College	Bengbu	Anhui
China	China-Japan Union Hospital of Jilin University	Changchun	Jilin
China	Jilin Provincial People's Hospital	Changchun	Jilin
China	The Second Xiangya Hospital of Central South University	Changsha	Hunan
China	The First Affiliated Hospital of Chengdu Medical College	Chengdu	Sichuan
China	Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University	Guangzhou	Guangdong
China	First Affiliated Hospital,Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Zhejiang Provincial People's Hospital	Hangzhou	Zhejiang
China	Anhui provincial hospital	Hefei	Anhui
China	Jiu Jiang NO.1 people's Hospital	Jiujiang	Jiangxi
China	Linyi people's Hospital	Linyi	Shandong
China	Jiangsu Provincial Hospital	Nanjing	Jiangsu
China	Jiangxi Pingxiang people's Hospital	Pingxiang	Jiangxi
China	Huashan Hospital Affiliated to Fudan University	Shanghai	Shanghai
China	Renji Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Tongji Hospital Of Tongji University Tang Jianping	Shanghai	Shanghai
China	Zhongshan Hospital Affiliated to Fudan University	Shanghai	Shanghai
China	The University of Hong Kong-Shenzhen Hospital	Shenzhen	Guangdong
China	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu
China	People's Hospital of Xinjiang Uygur Autonomous Region	Ürümqi	Xinjiang
China	The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	Zhejiang
China	The First Affiliated Hospital of Xiamen University	Xiamen	Fujian
China	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Hemay Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to evaluate the efficacy of Hemay005 in the treatment of Behçet's disease.	Area under the curve (AUC) for the number of oral ulcers from baseline through Week 12	week 12
Secondary	Proportion of subjects achieving an oral ulcer complete response	Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) by Week 6 after dosing, and who remain oral ulcer free for at least 6 additional weeks during the Treatment Phase	week 6
Secondary	Complete response rate for oral ulcers	Complete response rate for oral ulcers at day 3, day 7 and Week 12	day 3, day 7 and week12
Secondary	change of the pain evaluation of oral ulcers as measured by Visual analogue scale(VAS)(From 0-100, the higher score means the worse outcome)	Change from baseline in the pain of oral ulcers as measured by VAS at Week 12	week12
Secondary	change of the number of oral ulcers	Change from baseline in the number of oral ulcers at Week 12	week12
Secondary	Time to oral ulcer resolution	Time to oral ulcer resolution (complete response) that the first instance when a subject has a complete response during the core-Treatment Phase	week12
Secondary	Proportion of subjects achieving an oral ulcer complete response in the core-treatment phase	Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) and who remain oral ulcer free during the core-treatment Phase	week12
Secondary	Number of oral ulcers who has a reappearance during the core-treatment phase	Number of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase	week12
Secondary	Time to oral ulcer reappearance during the core-treatment	Time to recurrence of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase	week12
Secondary	change of the total score of Physician's Global Assessment(PGA)	change from baseline in the total score of the PGA of skin lesions of BD at week 12 in those subjects who had at baseline	week12
Secondary	change of BD Current Activity Form(BDCAF)	change from baseline in the total score of the BDCAF questionnaire at week 12	week12
Secondary	change of Multi-Dimensional Health Assessment Questionnaire (MDHAQ)	change from baseline in the total score of the MDHAQ questionnaire at week 12	week12
Secondary	change of short from health survey(SF-36)	change from baseline in the total score of the SF-36 questionnaire at week 12	week12
Secondary	Complete response rate for genital ulcers	Complete response rate for genital ulcers at Week 12 for subjects who had genital ulcers at Baseline	week12
Secondary	change of the pain evaluation of genital ulcers	Change from baseline in the pain of genital ulcers as measured by VAS at Week 12	week12
Secondary	Change of the Behçet's syndrome activity score(BSAS) score	Change from Baseline in BSAS score at Week 12	week12
Secondary	Maximum Plasma Concentration (Cmax)	the population pharmacokinetic (popPK) characteristics Cmax of Hemay005 in BD patients	week24
Secondary	Minimum Plasma Concentration (Cmin)	the population pharmacokinetic (popPK) characteristics Cmin of Hemay005 in BD patients	week24
Secondary	Time to peak (Tmax)	the population pharmacokinetic (popPK) characteristics Tmax of Hemay005 in BD patients	week24
Secondary	Elimination half-life (T1/2)	the population pharmacokinetic (popPK) characteristics T1/2 of Hemay005 in BD patients	week24
Secondary	Area under drug time curve (AUC)	the population pharmacokinetic (popPK) characteristics AUC of Hemay005 in BD patients	week24
Secondary	Clearance (Cl)	the population pharmacokinetic (popPK) characteristics Cl of Hemay005 in BD patients	week24
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])	the Incidence of Treatment-Emergent Adverse Events of Hemay005 in BD patients with different dosing group	week24
Secondary	the number of subjects who terminated hemay005 prematurely due to adverse events (AE) [Safety and Tolerability])	the number of subjects who terminated hemay005 prematurely due to adverse events (AE) in BD patients with different dosing group	week24